Multi-locus variable-number tandem repeat analysis of Bordetella pertussis isolates circulating in Poland in the period 1959–2013

Mosiej, Ewa; Krysztopa-Grzybowska, Katarzyna; Polak, Maciej; Prygiel, Marta; Lutyńska, Anna

doi:10.1099/jmm.0.000408

Cited by 9 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genetic changes observed in the B. pertussis isolates circulating in Poland seem to be driven slightly differently compared to elsewhere in Europe [ 20 ]. All B. pertussis isolates from pertussis patients in Poland after 1995 had the non-vaccine allele of the subunit S1 of pertussis toxin ( ptxA1 ).…”

Section: Introductionmentioning

confidence: 99%

“…All B. pertussis isolates from pertussis patients in Poland after 1995 had the non-vaccine allele of the subunit S1 of pertussis toxin ( ptxA1 ). In the years 1995–2013, an increase in the incidence of isolates possessing non-vaccine alleles pertactin ( prn2, prn3 ), type 2 fimbriae ( fim2-2 ) and pertussis toxin ( ptxC2 ) was observed [ 20 ]. This distinction may reflect differences in national vaccination strategies, as (unlike the other countries) the wP vaccine is still used in Poland and no changes of vaccine strain composition have been made [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model

Prygiel

Mosiej

Wdowiak

et al. 2021

Med Microbiol Immunol

Self Cite

View full text Add to dashboard Cite

The aim of this study was to compare the elimination of Bordetella pertussis clinical isolates, representing different genotypes in relation to alleles encoding virulence factors (MLST—multi-locus antigen sequence typing), MLVA type (multi-locus variable-number tandem repeat analysis) and PFGE group (pulsed-field gel electrophoresis) from the lungs of naive mice or mice were immunised with the commercial whole-cell pertussis vaccine, the acellular pertussis vaccine and the experimental whole-cell pertussis vaccine. Molecular data indicate that the resurgence of pertussis in populations with high vaccine coverage is associated with genomic adaptation of B. pertussis, to vaccine selection pressure. Pertactin-negative B. pertussis isolates were suspected to contribute to the reduced vaccine effectiveness. It was shown that one of the isolates used is PRN deficient. The mice were intranasally challenged with bacterial suspension containing approximately 5 × 10 7 CFU/ml B. pertussis. The immunogenicity of the tested vaccines against PT (pertussis toxin), PRN (pertactin), FHA (filamentous haemagglutinin) and FIM (fimbriae types 2 and 3) was examined. The commercial whole-cell and acellular pertussis vaccines induced an immunity effective at eliminating the genetically different B. pertussis isolates from the lungs. However, the elimination of the PRN-deficient isolate from the lungs of mice vaccinated with commercial vaccines was delayed as compared to the PRN ( +) isolate, suggesting phenotypic differences with the circulating isolates and vaccine strains. The most effective vaccine was the experimental vaccine with the composition identical to that of the strains used for infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model

Prygiel

Mosiej

Wdowiak

et al. 2021

Med Microbiol Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…MT27 was found to predominate in countries using acellular pertussis vaccines, including European [ 17, 18 ] and non-European countries, such as Australia [ 19 ], Japan [ 20 ] and the USA [ 21 ]. In countries currently using a whole-cell vaccine, such as Poland [ 22 ] and the Philippines [ 23 ], MTs other than MT27 are predominant. In Poland, MT29 (27 %) and MT70 (16 %) were found to predominate during the 54-year test period (1959–2013) [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

“…In countries currently using a whole-cell vaccine, such as Poland [ 22 ] and the Philippines [ 23 ], MTs other than MT27 are predominant. In Poland, MT29 (27 %) and MT70 (16 %) were found to predominate during the 54-year test period (1959–2013) [ 22 ]. In the Philippines, MT34 (50 %) (2012–2014) – a rare MT in Europe, Australia, Japan and the USA – was predominant [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular epidemiology of Bordetella pertussis in Greece, 2010–2015

Petridou

Jensen

Arvanitidis

et al. 2018

Journal of Medical Microbiology

View full text Add to dashboard Cite

PurposeTo determine the predominant strains of Bordetella pertussis in Greece during 2010–2015.MethodologyInfants and children (n=1150) (15 days to 14 years) of Greek, Roma and immigrant origin with different vaccination statuses were hospitalized in Athens, Greece with suspected pertussis infection. IS481/IS1001 real-time PCR confirmed Bordetella spp./B. pertussis infection in 300 samples. A subset of samples (n=153) were analysed by multi-locus variable number tandem repeat analysis (MLVA) and (n=25) by sequence-based typing of the toxin promotor region (ptxP) on DNA extracted from clinical specimens.Results/Key findingsA complete MLVA profile was determined in 66 out of 153 samples; the B. pertussis MLVA type 27 (n=55) was the dominant genotype and all tested samples (n=25) expressed the ptxP3 genotype. The vaccine coverage in the Greek population was 90 %; however, the study population expressed complete coverage in 2 out of 264 infants (0–11 months) and in 20 out of 36 children (1–14 years). Roma and immigrant minorities represent 7 % of the Greek population, but make up 50 % of the study population, indicating a low vaccine coverage among these groups.ConclusionsThe B. pertussis MT27 and ptxP3 genotype is dominant in Greek, Roma and immigrant infants and children hospitalized in Greece. Thus, the predominant MLVA genotype in Greece is similar to other countries using acellular vaccines.

show abstract

“…Незважаючи на те, що вакцину проти кашлюка винайшли у 1943 році, кашлюк залишається проблемою в багатьох країнах світу. В Польші кашлюк вважається найбільш поширеним захворюванням серед усіх імунокерованих хвороб [1]. В Аргентині відмічається підвищена настороженість медичних працівників щодо захворювання на кашлюк осіб різного віку з метою ранньої діагностики та своєчасного реагування.…”

unclassified

Захворюваність На Кашлюк У Львівській Області

Іванченко¹

2021

View full text Add to dashboard Cite

show abstract

Multi-locus variable-number tandem repeat analysis of Bordetella pertussis isolates circulating in Poland in the period 1959–2013

Cited by 9 publications

References 43 publications

Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model

Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model

Molecular epidemiology of Bordetella pertussis in Greece, 2010–2015

Захворюваність На Кашлюк У Львівській Області

Contact Info

Product

Resources

About